Home » Roche Wins International Erythropoietin Dispute
Roche Wins International Erythropoietin Dispute
September 8, 2006
The U.S. International Trade Commission (ITC) has decided not to review a decision made earlier this year that Roche’s importation and use of its experimental anemia drug Mircera in the U.S. did not violate Amgen’s patents on its anemia drug Epogen. Roche will continue to focus on obtaining FDA approval for Mircera, it said in a Sept. 1 statement.